These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8971169

  • 1. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
    Siders WM, Halloran PJ, Fenton RG.
    Cancer Res; 1996 Dec 15; 56(24):5638-46. PubMed ID: 8971169
    [Abstract] [Full Text] [Related]

  • 2. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
    Siders WM, Halloran PJ, Fenton RG.
    Cancer Gene Ther; 1998 Dec 15; 5(5):281-91. PubMed ID: 9824047
    [Abstract] [Full Text] [Related]

  • 3. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O.
    Cancer Gene Ther; 2005 Nov 15; 12(11):864-72. PubMed ID: 15891771
    [Abstract] [Full Text] [Related]

  • 4. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
    Emiliusen L, Gough M, Bateman A, Ahmed A, Voellmy R, Chester J, Diaz RM, Harrington K, Vile R.
    Gene Ther; 2001 Jul 15; 8(13):987-98. PubMed ID: 11438833
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo targeting of gene expression to melanoma cells.
    Vile RG, Hart IR.
    Cancer Res; 1993 Mar 01; 53(5):962-7. PubMed ID: 8439971
    [Abstract] [Full Text] [Related]

  • 6. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
    Schoensiegel F, Paschen A, Sieger S, Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D, Haberkorn U.
    Cancer Gene Ther; 2004 Jun 01; 11(6):408-18. PubMed ID: 15118759
    [Abstract] [Full Text] [Related]

  • 7. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.
    Int J Oncol; 2007 Nov 01; 31(5):1177-85. PubMed ID: 17912445
    [Abstract] [Full Text] [Related]

  • 8. Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
    Artuc M, Nürnberg W, Czarnetzki BM, Schadendorf D.
    Biochem Biophys Res Commun; 1995 Aug 15; 213(2):699-705. PubMed ID: 7646526
    [Abstract] [Full Text] [Related]

  • 9. A novel attenuated replication-competent adenovirus for melanoma therapy.
    Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S.
    Gene Ther; 2003 Apr 15; 10(7):530-9. PubMed ID: 12646858
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM, Rivera AA, Balagué C, Alemany R, Curiel DT.
    Cancer Res; 2002 Aug 15; 62(16):4663-70. PubMed ID: 12183423
    [Abstract] [Full Text] [Related]

  • 14. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 2004 Apr 15; 11(4):256-62. PubMed ID: 15017380
    [Abstract] [Full Text] [Related]

  • 15. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC, Sakamoto GT, Henderson DR.
    Cancer Res; 1999 Apr 01; 59(7):1498-504. PubMed ID: 10197620
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Zhang ZW, Guo YL.
    Cancer Gene Ther; 2004 Apr 01; 11(4):263-72. PubMed ID: 14963492
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.